NIH awards grant to develop 'TurboTax for eligibility for public health'

The National Institutes of Health has awarded a five-year, $1.6 million grant to a firm focusing on developing software to ease determining eligibility for public health programs.

According to the Milwaukee Journal Sentinel, My Coverage Plan Inc., a subsdiary of public interest firm ABS for Health, will try to develop software to help train hospital staff, including administrators and financial counselors, in eligibility requirements of Medicaid, Medicare and other programs.

The company hopes such a product could increase usage of public health programs and reduce debt-related expenses for hospitals.

"NIH understands these technologies are slow to develop," Peterson said. "They are not something that you can just roll out."

My Coverage Plan previously received two multiyear grants — one totaling $1.2 million and the other totaling $400,000 — from the National Institutes of Health.

"These grants are the fuel to get us started," Peterson said.

My Coverage Plan has partnered with St. Mary's Hospital in Madison, Wisc., and will soon start testing the software system.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.